• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following EBV

Murph

:)
Messages
1,799
Brain Behav Immun. 2019 Apr 27. pii: S0889-1591(19)30133-3. doi: 10.1016/j.bbi.2019.04.040. [Epub ahead of print]
Clinical symptoms and markers of disease mechanisms in adolescent chronic fatigue following Epstein-Barr virus infection: An exploratory cross-sectional study.
Kristiansen MS1, Stabursvik J1, O'Leary EC1, Pedersen M1, Asprusten TT1, Leegaard T2, Osnes LT3, Tjade T4, Skovlund E5, Godang K6, Wyller VBB7.
Author information

Abstract
INTRODUCTION:
Acute Epstein-Barr virus (EBV) infection is a trigger of chronic fatigue (CF) and Chronic Fatigue Syndrome (CFS). The aim of this cross-sectional study was to explore clinical symptoms as well as markers of disease mechanisms in fatigued and non-fatigued adolescents 6 months after EBV-infection, and in healthy controls.
MATERIALS AND METHODS:
A total of 200 adolescents (12-20 years old) with acute EBV infection were assessed 6 months after the initial infectious event and divided into fatigued (EBV CF+) and non-fatigued (EBV CF-) cases based on questionnaire score. The EBV CF+ cases were further sub-divided according to case definitions of CFS. In addition, a group of 70 healthy controls with similar distribution of sex and age was included. Symptoms were mapped with a questionnaire. Laboratory assays included EBV PCR and serology; detailed blood leukocyte phenotyping and serum high-sensitive C-reactive protein; and plasma and urine cortisol and catecholamines. Assessment of autonomic activity was performed with continuous, non-invasive monitoring of cardiovascular variables during supine rest, controlled breathing and upright standing. Differences between EBV CF+ and EBV CF- were assessed by simple and multiple linear regression adjusting for sex as well as symptoms of depression and anxiety. A p-value ≤ 0.05 was considered statistically significant. This study is part of the CEBA-project (Chronic fatigue following acute Epstein-Barr virus infection in adolescents).

RESULTS:
The EBV CF+ group had significantly higher scores for all clinical symptoms. All markers of infection and most immune, neuroendocrine and autonomic markers were similar across the EBV CF+ and EBV CF- group. However, the EBV CF+ group had slightly higher serum C-reactive protein (0.48 vs 0.43 mg/L, p=0.031, high-sensitive assay), total T cell (CD3+) count (median 1573 vs 1481 x 106 cells/L, p=0.012), plasma norepinephrine (1420 vs 1113 pmol/L, p=0.01) and plasma epinephrine (363 vs 237 nmol/L, p=0.032); lower low-frequency:high frequency (LF/HF) ratio of heart rate variability at supine rest (0.63 vs 0.76, p=0.008); and an attenuated decline in LF/HF ratio during controlled breathing (-0.11 vs -0.25, p=0.002). Subgrouping according to different CFS diagnostic criteria did not significantly alter the results. Within the EBV CF+ group, there were no strong correlations between clinical symptoms and markers of disease mechanisms. In a multiple regression analysis, serum CRP levels were independently associated with serum cortisol (B= 4.5 x 10-4, p<0.001), urine norepinephrine (B=9.6 x 10-2, p=0.044) and high-frequency power of heart rate variability (B= -3.7 x 10-2, p=0.024).

CONCLUSIONS:
In adolescents, CF and CFS 6 months after acute EBV infection are associated with high symptom burden, but no signs of increased viral load and only subtle alterations of immune, autonomic, and neuroendocrine markers of which no one is strongly correlated with symptom scores. A slight sympathetic over parasympathetic predominance is evident in CF and might explain slightly increased CRP levels.

Copyright © 2019. Published by Elsevier Inc.
PMID: 31039432 DOI: 10.1016/j.bbi.2019.04.040
 

Rufous McKinney

Senior Member
Messages
13,393
not to sure what to make of it as it

Not sure either. So did they simply measure various processes which are NOT where the actual issues reside? (our story whenever we get tested, they don't find 'anything" because they aren't looking at the right part eg they don't look at deformability ,or BBB weaknesses, or viral load, or your gut composition).

Out of 200 adolescent, and six months....thats not enough time to develop more serious symptoms perhaps in the majority of vulnerable people? But yet we do have the adolescent who becomes severe and bed-ridden.

For me: repeated rounds of acute Eppstein Barr (4 times) did not lead directly to major incapacitation. It took many many years to achieve the deteriorated state I am now in.
 

Art Vandelay

Senior Member
Messages
470
Location
Australia
Had another read of it. Looks like yet another attempt to show that Chronic Fatigue Syndrome is all in the mind by mixing it up with chronic fatigue. Oh and ignoring the quantity of research that shows it is not all in the mind.

Given that one of the authors in particular is well known for favouring pseudo-scientific explanations for ME/CFS and psychobabble-type treatments (including music therapy and the Lightning Process, I kid you not), you're no doubt correct.

More junk science.